Intuitive Surgical Q2: Procedures Up 16%, Revenue Up 19% as Margin Outlook Improves

Transcript intelligence

What changed

Q2 procedures grew 16% YoY (vs. 17% in Q1), with da Vinci up 15% and ION up 36%. Revenue increased 19% to $2.89 billion (vs. 23% growth and $2.77 billion in Q1), with non-GAAP operating margin at 42%. System placements rose 18% YoY to 468 da Vinci and 55 ION units (vs. 431 and 52 in Q1). The guidance stance moved from raised to maintained, though the non-GAAP gross margin outlook was lifted to 68-69% from 67.5-68.5%. EPS of $2.80 beat consensus of $2.48 by 13%. Three new disclosures marked the quarter: the extended-use instrument program targeting commercial launch in H1 2027, a non-commercial flexible GI robotic endoscope submitted for FDA 510(k) clearance, and instrument encryption technology to enhance product security. Japan added reimbursement for seven additional procedures effective June 1. The stock initially rose roughly 4% on the report but subsequently drifted approximately 10% lower through July 28.

Guidance delta

Management reaffirmed 2026 guidance rather than raising it, marking a shift from Q1's raised posture. The non-GAAP gross margin outlook was lifted to 68-69% from the prior 67.5-68.5%. The da Vinci procedure growth range established in Q1 at 13.5-15.5% was not revised further. Capex outlook remained stable. The maintained stance, combined with new questions about the extended-use program's potential impact on instruments and accessories revenue, likely contributed to the post-earnings stock drift.

Key takeaways

• Procedures grew 16% YoY with da Vinci up 15% and ION up 36%
• Revenue increased 19% on an 18% constant-currency basis to $2.89 billion
• System placements rose 18% YoY, with 468 da Vinci and 55 ION installations including growth in cost-sensitive markets via XiR
• Management reaffirmed 2026 guidance, raising non-GAAP gross margin outlook to 68-69% from 67.5-68.5%
• New initiatives -- extended-use instruments, GI robot development, and instrument encryption -- aim to expand market penetration but introduce per-procedure revenue uncertainty

Management priorities

• Roll out over 100 software and feature updates for da Vinci 5 throughout 2027
• Commercial launch of the extended-use instrument program in H1 2027
• Progress GI robotic endoscope through FDA regulatory review and clinical evidence generation
• Further penetrate XiR in ASC and international cost-sensitive markets
• Continue investment in AI, machine learning, and advanced materials across platforms